EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer

• Published in: International journal of molecular sciences Vol. 17; no. 12; p. 2132
• Main Authors: Tomasini, Pascale, Serdjebi, Cindy, Khobta, Nataliya, Metellus, Philippe, Ouafik, L'Houcine, Nanni, Isabelle, Greillier, Laurent, Loundou, Anderson, Fina, Frederic, Mascaux, Celine, Barlesi, Fabrice
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18-12-2016; MDPI
• Subjects: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors - therapeutic use; Bevacizumab - therapeutic use; Brain cancer; brain metastasis; Brain Neoplasms - drug therapy; Brain Neoplasms - genetics; Brain Neoplasms - secondary; Cancer; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; EGFR; Female; Humans; incidence; KRAS; Life Sciences; Lung cancer; lung neoplasm; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Male; Metastasis; Middle Aged; Mutation; Neoplasm Recurrence, Local - pathology; Proto-Oncogene Proteins p21(ras) - genetics; Receptor, Epidermal Growth Factor - genetics; recurrence; survival; Treatment Outcome; recurrence; lung neoplasm; survival; KRAS; brain metastasis; incidence; EGFR
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms17122132

Lung cancer is the leading cause of brain metastases (BM). The identification of driver oncogenes and matched targeted therapies has improved outcome in non-small cell lung cancer (NSCLC) patients; however, a better understanding of BM molecular biology is needed to further drive the process in this field.
In this observational study, stage IV NSCLC patients tested for
and
mutations were selected, and BM incidence, recurrence and patients' outcome were assessed.
A total of 144 patients (142 Caucasian and two Asian) were selected, including 11.27% with
-mutant and 33.10% with
-mutant tumors, and 57.04% patients had developed BM. BM incidence was more frequent in patients with
mutation according to multivariate analyses (MVA) (Odds ratio OR = 8.745 [1.743-43.881],
= 0.008). Among patients with treated BM, recurrence after local treatment was less frequent in patients with
mutation (OR = 0.234 [0.078-0.699],
= 0.009). Among patients with untreated BM, overall survival (OS) was shorter for patients with
mutation according to univariate analysis (OR = 7.130 [1.240-41.012],
= 0.028), but not MVA.
and
mutations have a predictive role on BM incidence, recurrence and outcome in Caucasian NSCLC patients. These results may impact the routine management of disease in these patients. Further studies are required to assess the influence of other biomarkers on NSCLC BM.